GALECTIN THERAPEUTICS INC (GALT) Fundamental Analysis & Valuation

NASDAQ:GALT • US3632252025

Current stock price

2.56 USD
-0.11 (-4.12%)
At close:
2.56 USD
0 (0%)
Pre-Market:

This GALT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. GALT Profitability Analysis

1.1 Basic Checks

  • GALT had negative earnings in the past year.
  • In the past year GALT has reported a negative cash flow from operations.
  • GALT had negative earnings in each of the past 5 years.
  • GALT had a negative operating cash flow in each of the past 5 years.
GALT Yearly Net Income VS EBIT VS OCF VS FCFGALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • With a Return On Assets value of -158.58%, GALT is not doing good in the industry: 84.91% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -158.58%
ROE N/A
ROIC N/A
ROA(3y)-195.75%
ROA(5y)-168.64%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GALT Yearly ROA, ROE, ROICGALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GALT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GALT Yearly Profit, Operating, Gross MarginsGALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. GALT Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, GALT has more shares outstanding
  • GALT has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, GALT has a worse debt to assets ratio.
GALT Yearly Shares OutstandingGALT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
GALT Yearly Total Debt VS Total AssetsGALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • GALT has an Altman-Z score of -33.00. This is a bad value and indicates that GALT is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -33.00, GALT is not doing good in the industry: 90.14% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -33
ROIC/WACCN/A
WACCN/A
GALT Yearly LT Debt VS Equity VS FCFGALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • GALT has a Current Ratio of 2.42. This indicates that GALT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.42, GALT is doing worse than 71.76% of the companies in the same industry.
  • GALT has a Quick Ratio of 2.42. This indicates that GALT is financially healthy and has no problem in meeting its short term obligations.
  • GALT has a Quick ratio of 2.42. This is in the lower half of the industry: GALT underperforms 69.05% of its industry peers.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2.42
GALT Yearly Current Assets VS Current LiabilitesGALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GALT Growth Analysis

3.1 Past

  • GALT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.84%, which is quite impressive.
EPS 1Y (TTM)36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • GALT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.96% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.13%
EPS Next 2Y13.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GALT Yearly Revenue VS EstimatesGALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 100M 200M 300M 400M 500M
GALT Yearly EPS VS EstimatesGALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8

More info and screens

Find the best growth stocksShow best growing peers

0

4. GALT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GALT. In the last year negative earnings were reported.
  • Also next year GALT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GALT Price Earnings VS Forward Price EarningsGALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GALT Per share dataGALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GALT's earnings are expected to grow with 13.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.96%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GALT Dividend Analysis

5.1 Amount

  • No dividends for GALT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GALT Fundamentals: All Metrics, Ratios and Statistics

GALECTIN THERAPEUTICS INC

NASDAQ:GALT (4/6/2026, 8:00:02 PM)

Premarket: 2.56 0 (0%)

2.56

-0.11 (-4.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31
Earnings (Next)05-13
Inst Owners18%
Inst Owner Change0%
Ins Owners19.35%
Ins Owner Change-2.46%
Market Cap168.52M
Revenue(TTM)N/A
Net Income(TTM)-30.97M
Analysts82.86
Price Target11.22 (338.28%)
Short Float %14.53%
Short Ratio21.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.85%
Min EPS beat(2)-15.86%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)14.66%
Min EPS beat(4)-15.86%
Max EPS beat(4)26.47%
EPS beat(8)4
Avg EPS beat(8)1.88%
EPS beat(12)7
Avg EPS beat(12)0.93%
EPS beat(16)9
Avg EPS beat(16)2.32%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0
BVpS-1.92
TBVpS-1.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.58%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-195.75%
ROA(5y)-168.64%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 2.42
Altman-Z -33
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.89%
EPS Next Y34.13%
EPS Next 2Y13.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y52.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.64%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.84%
OCF growth 3YN/A
OCF growth 5YN/A

GALECTIN THERAPEUTICS INC / GALT Fundamental Analysis FAQ

What is the fundamental rating for GALT stock?

ChartMill assigns a fundamental rating of 1 / 10 to GALT.


What is the valuation status for GALT stock?

ChartMill assigns a valuation rating of 0 / 10 to GALECTIN THERAPEUTICS INC (GALT). This can be considered as Overvalued.


What is the profitability of GALT stock?

GALECTIN THERAPEUTICS INC (GALT) has a profitability rating of 0 / 10.


Is the dividend of GALECTIN THERAPEUTICS INC sustainable?

The dividend rating of GALECTIN THERAPEUTICS INC (GALT) is 0 / 10 and the dividend payout ratio is 0%.